Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.55 |
| ▸ | TACR2 | P21452 | 2/20 | 0.52 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.49 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599650 | 1.00 | LTA4H (0.58) | LTA4HFOLH1TACR2TAOK1TAOK3 | |
| SCHEMBL4599893 | 0.97 | LTA4H (0.59) | LTA4HFOLH1TACR2TAOK1TAOK3 | |
| SCHEMBL4599880 | 0.97 | LTA4H (0.59) | LTA4HFOLH1TACR2TAOK1TAOK3 | |
| SCHEMBL4598883 | 0.89 | LTA4H (0.67) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL4600092 | 0.89 | LTA4H (0.67) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL4599431 | 0.89 | LTA4H (0.67) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL4598874 | 0.88 | LTA4H (0.66) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL4598882 | 0.88 | LTA4H (0.66) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL4600154 | 0.87 | LTA4H (0.62) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL4599694 | 0.87 | LTA4H (0.62) | LTA4HCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | LTA4H 2507/4885FOLH1 771/4885TACR2 2976/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | LTA4H 1884/4885FOLH1 1486/4885TACR2 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.